Biomed Solutions develops and invests in business opportunities based upon a strong foundation of intellectual property. We hold equity interests in public and private companies, and patents covering a wide variety of innovations involved in future advances in medical devices and treatments.
Biophan's mission is to enable biomedical devices to be MRI safe and image compatible. We offer proprietary thin-film nanomagnetic particle and carbon composite polymer MRI shielding, RF filtering technology originally developed at Johns Hopkins University, and MRI safe fiber-optic catheters for a variety of devices from pacemakers to endoscopes. Our technology allows biomedical device manufacturers to offer MRI safe products.
Myotech, LLC, is a privately-held medical device development company, formed to commercialize a family of medical products based upon Direct Mechanical Ventricular Actuation (DMVA) cardiac support technology. This technology has permitted the development of a new heart pump that promises to be broadly available to treat patients with many types of heart failure. Myotech has relationships with leading industry experts, physicians, and medical institutions to assist the Company in the commercialization of the Myotech Circulatory Support System.
NaturalNano Inc. is based in Rochester, New York and was founded in 2004 to discover, refine, and commercialize naturally occurring nanoscale materials. The Company's near-term goal is to make commercial quantities of high-quality naturally occurring nanotubes -- along with licenses based on the Company's proprietary technologies -- available for a wide variety of uses. These include applications in engineered plastics and polymers, cosmetics and other personal care products, absorbent materials, and electronic components. More than 200 applications have been identified
OncoVista is a privately held developement-stage pharmaceutical company dedicated to providing innovative, safe, and efficacious treatments for cancer and other life threatening diseases. The combination of OncoVista's extensive in-house preclinical and clinical expertise with our global drug developement network will lead to rapid and cost -effective regulatory approval and commercialization of novel therapies for the treatment of cancer.